The abstract is read at the publisher; the summary is JClub's.
The design-build-test-learn (DBTL) framework coordinates computational discovery, peptide production, experimental evaluation, and iterative optimization to improve antimicrobial peptide candidates.
- Why it matters: Antimicrobial resistance is driving demand for anti-infective options beyond conventional drugs, but AMP translation is limited by physiological instability, host toxicity, and high manufacturing costs.
- What they did: The review describes DBTL workflows using proteome mining and generative artificial intelligence to expand sequence space, then solid-phase synthesis, engineered microbial hosts, or cell-free systems for testing, with chemical modification and formulation for stability and delivery.
- The result: Standardized screening and in vivo studies generate evidence to prioritize candidates while jointly optimizing activity, toxicity, stability, manufacturability, and delivery, though practical impact depends on validated feedback and application-specific criteria.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.